Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) Equity Average (2024 - 2025)

Kairos Pharma's Equity Average history spans 2 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Equity Average rose 52.17% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, up 52.17%, while the annual FY2025 figure was $5.6 million, N/A changed from the prior year.
  • Equity Average reached $6.2 million in Q4 2025 per KAPA's latest filing, down from $6.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $6.6 million in Q2 2025 to a low of -$2.5 million in Q2 2024.